Collins Ian, Caldwell John, Fonseca Tatiana, Donald Alastair, Bavetsias Vassilios, Hunter Lisa-Jane K, Garrett Michelle D, Rowlands Martin G, Aherne G Wynne, Davies Thomas G, Berdini Valerio, Woodhead Steven J, Davis Deborah, Seavers Lisa C A, Wyatt Paul G, Workman Paul, McDonald Edward
Cancer Research, UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey.
Bioorg Med Chem. 2006 Feb 15;14(4):1255-73. doi: 10.1016/j.bmc.2005.09.055. Epub 2005 Oct 24.
Structure-based drug design of novel isoquinoline-5-sulfonamide inhibitors of PKB as potential antitumour agents was investigated. Constrained pyrrolidine analogues that mimicked the bound conformation of linear prototypes were identified and investigated by co-crystal structure determinations with the related protein PKA. Detailed variation in the binding modes between inhibitors with similar overall conformations was observed. Potent PKB inhibitors from this series inhibited GSK3beta phosphorylation in cellular assays, consistent with inhibition of PKB kinase activity in cells.
研究了基于结构的新型异喹啉-5-磺酰胺类PKB抑制剂作为潜在抗肿瘤药物的药物设计。通过与相关蛋白PKA的共晶体结构测定,鉴定并研究了模拟线性原型结合构象的受限吡咯烷类似物。观察到具有相似整体构象的抑制剂之间结合模式的详细变化。该系列中的强效PKB抑制剂在细胞试验中抑制了GSK3β磷酸化,这与细胞中PKB激酶活性的抑制一致。